Mesenchymal stem Cells and Extracellular Vesicles in Bladder Dysfunction: Mechanisms and Translational Perspectives
Stem Cell Reviews and Reports · 2026-11 · 22 (8) · 3439-3458
DOI: 10.1007/s12015-026-11209-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Stem Cell Reviews and Reports, online erschienen am 15.08.2026. Verfasst von Penghui Zhong und 5 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical College, Gannan Medical University, Jiangxi, Ganzhou, 341000, China. Hauptthemen laut MEDLINE: Extracellular Vesicles, Mesenchymal Stem Cells, Urinary Bladder, Urinary Bladder Diseases. Die Arbeit nennt 121 Literaturangaben. Gefördert von: Jiangxi Provincial Natural Science Foundation Joint Fund Project, Graduate Innovation Fund Project of Gannan Medical University.
Abstract (Originalsprache)
Bladder dysfunction comprises diverse lower urinary tract disorders lacking treatments that restore tissue integrity and neural control. While mesenchymal stem cells (MSCs) show promise in regenerative urology, their benefits primarily stem from paracrine mechanisms. Consequently, MSC-derived extracellular vesicles (MSC-EVs) have emerged as superior cell-free alternatives, recapitulating the parent cells' regenerative potential with enhanced biosafety, stability, and controllability.This review summarizes advances in MSC- and MSC-EV-based therapies for bladder conditions, including neurogenic, diabetic, overactive/underactive bladder, outlet obstruction, and interstitial cystitis. Mechanistically, these therapies exert multi-target effects: modulating immunity, suppressing fibrosis (via TGF-β inhibition), attenuating inflammation (via NF-κB/NLRP3), promoting angiogenesis, and enhancing neuroregeneration. MSC-EVs drive these processes by precisely transferring bioactive microRNAs and proteins.We propose a paradigm shift from conventional cell therapies to MSC-EV-centric, cell-free strategies, which overcome traditional transplantation limitations like low engraftment and immunogenicity. While early data confirm feasibility and safety, challenges in standardizing EV isolation, dosing, and long-term efficacy remain. Ultimately, this review establishes MSC-EVs as a next-generation therapeutic framework, guiding future clinical translation in regenerative urology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The First Clinical College, Gannan Medical University, Jiangxi, Ganzhou, 341000, China.
- Department of Urology, The First Affiliated hospital of Gannan Medical University, Jiangxi, Ganzhou, 341000, China.
- Institute of Urology, The First Affiliated hospital of Gannan Medical University, Jiangxi, Ganzhou, 341000, China.
- Department of Urology, The First Affiliated hospital of Gannan Medical University, Jiangxi, Ganzhou, 341000, China. zgx8778@163.com.
- Institute of Urology, The First Affiliated hospital of Gannan Medical University, Jiangxi, Ganzhou, 341000, China. zgx8778@163.com.
Förderung
- Jiangxi Provincial Natural Science Foundation Joint Fund Project
- Graduate Innovation Fund Project of Gannan Medical University
Zitieren
APA
Zhong, P., Chen, J., Cai, S., Zou, J., Zhong, X., & Zhang, G. (2026). Mesenchymal stem Cells and Extracellular Vesicles in Bladder Dysfunction: Mechanisms and Translational Perspectives. Stem Cell Reviews and Reports, 22(8), 3439-3458. https://doi.org/10.1007/s12015-026-11209-2
Vancouver
Zhong P, Chen J, Cai S, Zou J, Zhong X, Zhang G. Mesenchymal stem Cells and Extracellular Vesicles in Bladder Dysfunction: Mechanisms and Translational Perspectives. Stem Cell Reviews and Reports. 2026;22(8):3439-3458. doi:10.1007/s12015-026-11209-2
BibTeX
@article{Zhong2026,
author = {Zhong, Penghui and Chen, Jin and Cai, Shijie and Zou, Junrong and Zhong, Xuyang and Zhang, Guoxi},
title = {Mesenchymal stem Cells and Extracellular Vesicles in Bladder Dysfunction: Mechanisms and Translational Perspectives},
journal = {Stem Cell Reviews and Reports},
year = {2026},
volume = {22},
number = {8},
pages = {3439--3458},
doi = {10.1007/s12015-026-11209-2}
}
EUVIMED